Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
Yoshitaka Tada, Tetsuya Nakatsura(Unknown), Daisuke Nobuoka(Fukuyama City Hospital), Manami Shimomura(National Cancer Center Hospital East), Mayuko Sakai(National Cancer Center Hospital East), Yu Sawada(Shizuoka Cancer Center), Hirofumi Shirakawa(Shizuoka Cancer Center), Toshiaki Yoshikawa(Aichi Cancer Center)
Cited by 25
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178
Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy
|Cell stem cell|2018|163
Risk factors for major morbidity after liver resection for hepatocellular carcinoma
|British journal of surgery|2012|104